Drug Profile
PRO 155
Alternative Names: PRO-155; Zebesten oftenoLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Laboratorios Sophia
- Class Eye disorder therapies; Nonsteroidal anti-inflammatories
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Ocular inflammation
Most Recent Events
- 01 Dec 2013 Phase-II clinical trials in Ocular inflammation in Mexico (Ophthalmic)
- 03 Aug 2012 Laboratorios Sophia plans a phase II trial for Ocular inflammation in Mexico (NCT01657266)
- 24 Feb 2012 Laboratorios Sophia completes enrolment in its phase I trial in Healthy volunteers in Mexico (NCT01535443)